Third Rock launches immuno-metabolism company Rheos

Immuno-metabolism company Rheos Medicines Inc. (Cambridge, Mass.) emerged from stealth mode with a $60 million series A round from Third Rock Ventures.

Rheos aims to discover and develop therapies targeting CD4+ T cells to treat inflammatory bowel disease (IBD), lupus and psoriasis, and therapies targeting CD8+ T cells to treat autoimmune thyroiditis, vitiligo and immuno-oncology indications (see BioCentury, March 22)...